The MAP congress is a one-of-a-kind meeting designed by a faculty of highly influential key opinion leaders to answer the need on how to integrate in daily practice the wealth of information coming from the analysis of tumour samples.
Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO) and UNICANCER are the organisers of this annual forum where the understanding of the tumour microenvironment as well as the impact of macroevolution and their connection to treatment resistance is a significant field of discussion in personalised medicine. New models, technologies, the current treatment advances available and new findings of ongoing clinical trials are vital to understanding which molecular alterations should be the object of therapeutic targets in cancer treatment.
Fast Facts: MAP 2018
- Expecting over 400 participants
- No parallel sessions
- Possibility to host a satellite symposium
- More than 28 key opinion leaders
- Excellent networking opportunities
How can I participate in the MAP 2018?
At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate their presence at our congress.
For sponsorship information and a prospectus please contact:
Head of Strategic Partnerships
We look forward to hearing from you!
Who has already signed up?
The MAP Organising partners gratefully acknowledge the valuable contribution the following organisations have made to the MAP 2018. (As of July 2018):
Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise at Bayer includes now four marketed products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
Roche, the world’s largest biotech company, leader in research-focused healthcare with strength in diagnostics, and Foundation Medicine a molecular information company are joining forces to help cancer patient with access to personalized care, providing an informative comprehensive genomic profiling (CGP) assay to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies and clinical trials.
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe. For further details please visit our website.
TESARO Bio France
TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. TESARO sees new possibilities to responsibly develop and commercialize innovative treatments where others may not.
For TESARO, Relationships are vital to the success of its activities, and the company commits to be a trusted partner to the cancer community
Incyte Biosciences International Sàrl
Incyte is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's web site.
Follow @Incyte on Twitter at twitter.com/Incyte.
OncoDNA helps oncologists select better treatments for patients. It combines advanced, comprehensive testing of disease biomarkers with a cancer treatment knowledge database which continuously ‘learns’ from scientific and medical advances. Four analyses are available: OncoDEEP®, OncoSTRAT&GO®, OncoTRACE™ and OncoSELECT®. Results report and follow-up data are accessible on the OncoSHARE® platform.
Educational Grant Supporters
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.